<DOC>
	<DOC>NCT00928343</DOC>
	<brief_summary>The purpose of the study is to evaluate the safety and tolerability of single ascending (SAD) subcutaneous and single oral dose of GLPG0187 compared to placebo. Also, pharmacokinetics (PK) and pharmacodynamics (PD) of GLPG0187 after single subcutaneous and oral administration will be evaluated, and, if applicable, the maximum tolerated dose determined.</brief_summary>
	<brief_title>First-in-Human Single Ascending Subcutaneous (s.c.) Dose and Single Oral Dose of GLPG0187</brief_title>
	<detailed_description />
	<criteria>healthy male, age 1850 years BMI between 1830 kg/mÂ², inclusive significantly abnormal platelet function or coagulopathy smoking drug or alcohol abuse</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>Safety</keyword>
	<keyword>Tolerability</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>